Key result
Liraglutide fails to reduce CV death or HF hospitalization post-MI vs. placebo.
Why the study?
Does liraglutide reduce cardiovascular death or hospitalization for heart failure in patients with type 2 diabetes following a myocardial infarction?
RCT (n=9,340)
Double-blind
Randomized
Yes
Does liraglutide reduce cardiovascular death or hospitalization for heart failure in patients with type 2 diabetes following a myocardial infarction?
While an incident myocardial infarction significantly increased the risk of subsequent cardiovascular death or heart failure hospitalization in patients with type 2 diabetes, continued treatment with liraglutide did not significantly reduce this risk compared to placebo.
Answers are grounded in this paper and cite their sources.
Liraglutide does not reduce post-MI CV death or HF hospitalization in T2D; challenges broader LEADER benefits and leaves dedicated post-MI trials needed.
OBJECTIVE: Animal studies demonstrated that glucagon-like peptide-1 receptor agonists reduce myocardial necrosis following regional ischaemia induction. This effect may improve cardiovascular outcomes after myocardial infarction. Risk of cardiovascular death or hospitalisation for heart failure after myocardial infarction was evaluated in patients with type 2 diabetes at high cardiovascular risk in the LEADER trial. METHODS: Data from patients randomised to liraglutide or placebo, in addition to standard of care, in Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) (NCT01179048) were analysed post hoc. Cox regression, with myocardial infarction as a time-dependent covariate, was used to analyse time from randomisation to a composite of cardiovascular death or hospitalisation for heart failure. RESULTS: Patients who experienced myocardial infarction had a sevenfold higher risk of the composite endpoint (with myocardial infarction: n = 148, 25.0%; without myocardial infarction: n = 716, 8.2%; hazard ratio: 7.0; 95% confidence interval: 5.8, 8.4). The risk of the composite endpoint after myocardial infarction was not significantly lower in the liraglutide group ( n = 63, 23.0%) compared with placebo ( n = 85, 26.7%; hazard ratio: 0.91; 95% confidence interval: 0.66, 1.26). CONCLUSION: The data demonstrated that having myocardial infarction significantly increased the risk of subsequent cardiovascular death or hospitalisation for heart failure. However, we did not find evidence for a reduced risk in these cardiovascular outcomes following myocardial infarction in patients treated with liraglutide versus placebo.
No takes yet. Share an insight, caveat, or question.
Nauck et al. (2018) conducted an RCT in Type 2 diabetes at high cardiovascular risk (n=9,340). Liraglutide vs. Placebo was evaluated on Composite of cardiovascular death or hospitalisation for heart failure after myocardial infarction (HR 0.91, 95% CI 0.66-1.26, p=not significant). Liraglutide did not reduce the risk of cardiovascular death or hospitalization for heart failure following a myocardial infarction compared with placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: